Evaluation of Efficacy and Safety of the Skinstylus Sterilock Microneedling System for the Treatment of Facial Wrinkles

NCT ID: NCT06032286

Last Updated: 2024-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-08

Study Completion Date

2024-05-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the efficacy and safety of the Skin stylus Sterilock microneedling system in reducing the appearance of facial wrinkles.This study is intended to be a single arm study. Suitable subjects who meet all inclusion criteria and consented will undergo 4 microneedling sessions at baseline and days 30, 60 and 90.

Subjects will be assessed at days 90, 120 and finally at day 150 by a physician utilizing the wrinkle grading scale developed by Lemperle (2001) and skin laxity and texture using a modified Alexiandes Armenakas (2010) grading scale.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is intended to be a single arm study. Suitable subjects who meet all inclusion criteria and consented will undergo 4 microneedling sessions at baseline and days 30, 60 and 90.

Subjects will be assessed at days 90, 120 and finally at day 150 by a physician utilizing the wrinkle grading scale developed by Lemperle (2001) and skin laxity and texture using a modified Alexiandes Armenakas (2010) grading scale.

Physicians will grade treatment response on days, 90, 120 and finally on day 150 using a Global Aesthetic Improvement Scale (GAIS) Standard photography will be recorded at baseline and days 30, 60, 90, 120 and finally at day 150.

Subjects will complete diaries including self-assessment of treatment response, side effects \& downtime up to 7 days post treatment.

Subjects will assess treatment response on days 90, 120 and finally on day 150 using a Subject Global Aesthetic Improvement Scale (SGAIS).

Subjects will assess treatment response and satisfaction at baseline and day 150 using the Facial Appearance, Health-Related Quality of Life and Adverse Effects (FACE-Q3) Patient reported outcome measure (PROM).

The number, type and severity of adverse events will be recorded during the duration of the study period.

At the end of the study period, photography will be assessed by three blinded physicians using the wrinkle grading scale developed by Lemperle (2001)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subjects Displaying Facial Ageing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single group, all subjects will receive intervention.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Microneedling

4 microneedling sessions at baseline and days 30, 60 and 90.

Group Type EXPERIMENTAL

Skinstylus microneedling device

Intervention Type DEVICE

Microneedling, also known as percutaneous collagen induction (PCI), is a minimally invasive technique where small needles create microscopic wounds in the skin inducing collagen formation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Skinstylus microneedling device

Microneedling, also known as percutaneous collagen induction (PCI), is a minimally invasive technique where small needles create microscopic wounds in the skin inducing collagen formation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male \& females; 35 to 75 years of age with signs of facial aging.
* Fitzpatrick I-VI phototype skin types.
* Volunteers with wrinkle grading of 1 to 4 according to Lemperle (2001) wrinkle grading scale.
* Volunteers with a laxity grading of 1-3.5 according to Alexiandes Armenakas (2010) grading scale.
* Written informed consent is given.
* Females of childbearing potential (FOCBP) and females who are premenses must be willing to practice effective contraception for the duration of the study. (Effective contraception is defined as stabilized on oral contraceptive for at least 3 months, intrauterine device, condom with spermicide, diaphragm with spermicide, implant, NuvaRing, injection, transdermal patch or abstinence.)
* Females on birth control pills must have taken the same type of pill for at least 3 months prior to entering the study and must not change type during the study.
* Those who have used birth control pills in the past must have discontinued usage at least 3 months prior to the start of the study.
* Volunteers agree NOT to use any topical agents containing active ingredients such as retinol, glycolic acid in the treatment area, during the study period.
* Volunteers agree NOT to undergo any aesthetic treatments (such as Botox, fillers, microdermabrasion, laser surfacing etc.) in the treatment area, during the study period.

Exclusion Criteria

* Volunteers have used a topical anti-aging product containing active ingredients within 4 weeks of commencing the study.
* Volunteers suffer from Hemophilia or other clotting/bleeding disorders.
* Volunteers taking anticoagulant therapy, e.g., warfarin, heparin.
* Volunteers who have used aspirin continuously in the last 2 weeks.
* Volunteers with active acne vulgaris of the face.
* Volunteers who have stopped taking birth control pills within the last 3 months.
* Volunteers suffer from uncontrolled diabetes mellitus.
* Volunteers with known malignancy and/or undergoing chemotherapy, radiotherapy, or high doses of corticosteroids.
* Volunteers suffer from keloid scars, Human Papilloma virus (HPV) or birth marks in the treatment area.
* Volunteers have a tendency for keloid scar formation.
* Volunteers suffer from eczema or skin rashes in the treatment area.
* Volunteers suffer from systemic infections such as hepatitis.
* Volunteers have known allergy to topical/local anesthetics.
* Volunteers have continuously used high dose NSAIDs for the last 2 weeks.
* Volunteers have undergone plastic surgery in the treatment area within the last 6 months.
* Volunteers have undergone filler injections in the treatment area within the last 6 months.
* Volunteers have received Botox or other neuromodulators injections in the treatment area within the last 6 months.
* Females who are pregnant, breast-feeding or who wish to become pregnant during the study period.
* Enrolled in another clinical trial during the same study period.
* Volunteer has a planned hospital admission and/or surgical procedure for an illness or disease which existed before enrolment into the clinical trial, and which may interfere with the course or outcome of the study.
* Volunteering has medical or psychological condition(s) associated with a risk of poor protocol compliance (e.g., alcoholism or drug abuse).
* Volunteer is undergoing or is likely to undergo other treatments.
Minimum Eligible Age

35 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beauty Health

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ablon Skin Institute

Manhattan Beach, California, United States

Site Status

West Dermatology Research Center

San Diego, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Lemperle G, Holmes RE, Cohen SR, Lemperle SM. A classification of facial wrinkles. Plast Reconstr Surg. 2001 Nov;108(6):1735-50; discussion 1751-2. doi: 10.1097/00006534-200111000-00048.

Reference Type BACKGROUND
PMID: 11711957 (View on PubMed)

Alexiades-Armenakas M. A quantitative and comprehensive grading scale for rhytides, laxity, and photoaging. J Drugs Dermatol. 2006 Sep;5(8):808-9. No abstract available.

Reference Type BACKGROUND
PMID: 16989197 (View on PubMed)

Pusic AL, Klassen AF, Scott AM, Cano SJ. Development and psychometric evaluation of the FACE-Q satisfaction with appearance scale: a new patient-reported outcome instrument for facial aesthetics patients. Clin Plast Surg. 2013 Apr;40(2):249-60. doi: 10.1016/j.cps.2012.12.001.

Reference Type BACKGROUND
PMID: 23506765 (View on PubMed)

Orentreich DS, Orentreich N. Subcutaneous incisionless (subcision) surgery for the correction of depressed scars and wrinkles. Dermatol Surg. 1995 Jun;21(6):543-9. doi: 10.1111/j.1524-4725.1995.tb00259.x.

Reference Type BACKGROUND
PMID: 7773602 (View on PubMed)

Alster TS, Graham PM. Microneedling: A Review and Practical Guide. Dermatol Surg. 2018 Mar;44(3):397-404. doi: 10.1097/DSS.0000000000001248.

Reference Type BACKGROUND
PMID: 28796657 (View on PubMed)

Ablon G. Safety and Effectiveness of an Automated Microneedling Device in Improving the Signs of Aging Skin. J Clin Aesthet Dermatol. 2018 Aug;11(8):29-34. Epub 2018 Aug 1.

Reference Type RESULT
PMID: 30214664 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ASIRC_SSMS_07-14-23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Secretome Treatment for Facial Rejuvenation
NCT07227883 RECRUITING EARLY_PHASE1
Poly-L-lactic Acid for Skin Quality
NCT02003833 COMPLETED PHASE4